姓名

電話

E－mail

期刊論文：

1. Tu CC, Weng SY, Hsieh NC, Cheng WC, Alizargar J, Chang KS. Increasing Use of Telemedicine for Neurological Disorders During the COVID-19 Pandemic: A Mini-Review. Journal of Multidisciplinary Healthcare. 2023:16 Pages 411-418. (IF 2.919) 

2. Alizargar J, Hsieh NC, Wu SV, Weng SY. Using the Cardio-Ankle Vascular Index (CAVI) or the Mathematical Correction Form (CAVI0) in Clinical Practice. Int J Mol Sci. 2020 Mar 31;21(7):2410. (IF= 6.208)

3. Yin-Hsi Chang, Shih-Yen Weng, Sheng-Jie Shiue, Chao-Ling Cheng, Ming-Shun Wu. Hydrocele in recurrent acute pancreatitis caused by testicular venous obstruction A case report of a rare complication (CARE-compliant). Medicine. 2020 Mar (IF= 1.817)

4. Cheng-Hui Wang, Ting-Han Tai, Shih-Yen Weng, Shin-Wen Yeh, Ming-Shun Wu. (Two 1st authors). Spontaneous bacterial peritonitis caused by Campylobacter Coliin cirrhotic patient: A rare case report (CARE-compliant) Medicine. 2020 Mar 22. (IF= 1.817)

5. Muhammad Ashfaq-Khan , Misbah Aslam, Muhammad Asif Qureshi, Marcel Sascha Senkowski, Shih-Yen Weng, Susanne Strand, Yong Ook Kim, Geethanjali Pickert, Jörn M Schattenberg, Detlef Schuppan. Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. Sci Rep 2019 Nov 25;9(1):17463. (IF= 4.996)

6. Alizargar J, Hsieh NC, Wu SV, Weng SY. Comment on Lecca, L.I.; Portoghese, I.; Mucci, N.; Galletta, M.; Meloni, F.; Pilia, I.; Marcias, G.; Fabbri, D.; Fostinelli, J.; Lucchini, R.G.; Cocco, P.; Campagna, M. Association between Work-Related Stress and QT Prolongation in Male Workers. J. Environ. Res. Public Health 2019, 16, 4781.

7. Alizargar J, Bai CH, Hsieh NC, Wu SV, Weng SY, Wu JP. Association of Kidney Function Tests with a Cardio-Ankle Vascular Index in Community-Dwelling Individuals with a Normal or Mildly Decreased Estimated Glomerular Filtration Rate. Medicina (Kaunas). 2019 Sep 29;55(10):657. (IF= 2.948)

8. Cheng IC, Weng SY, Wu MS, Suk FM, Lien GS, Chen CN. Low-Molecular-Weight Fucoidan and High Stability Fucoxanthin Decrease Serum Alanine transaminase (ALT) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD)-A Double Blind, Randomized Controlled Trial. Advances in Digestive Medicine. 2019 Sep; 6: 116-122

9. Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, Regen T, Molokanova O, Chen T, Bopp T, Schild H, Brombacher F, Crosby JR, McCaleb ML, Waisman A, Bockamp E, Schuppan D. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. EBioMedicine. 2018;29:92-103. (IF 11.205)

10. Wang XY, Hausding M, Weng SY, Kim YO, Steven S, Klein T, Daiber A, Schuppan D. Gliptins suppress inflammatory macrophage activation to mitigate inflammation  and fibrosis in models of non-alcoholic steatohepatitis. Antioxidants & Redox Signaling. 2018;10;28(2):87-109. (IF 7.468).

11. Molokanova O, Schönig K, Weng SY, Wang X, Bros M, Diken M, Ohngemach S, Karsdal M, Strand D, Nikolaev A, Eshkind L, Schuppan D. Inducible knockdown of procollagen I protects mice from liver fibrosis and leads to dysregulated matrix genes and attenuated inflammation. Matrix Biol. 2018;66:34-49. (IF 10.447)

12. Lai CY, Liu H, Tin KX, Huang Y, Yeh KH, Peng HW, Chen HD, He JY, Chiang YJ, Liu CS, Weng SY, Tao MH, Yen JJ, Yang-Yen HF. Identification of UAP1L1 as a critical factor for protein O-GlcNAcylation and cell proliferation in human hepatoma cells. Oncogene. 2018 Aug 10, Epub ahead of print. (IF 8.756)

13. Haeberle S, Raker V, Haub J, Kim YO, Weng SY, Yilmaz OK, Enk A, Steinbrink K, Schuppan D, Hadaschik EN. Regulatory T cell deficient scurfy mice exhibit a Th2/M2-like inflammatory response in the skin. J Dermatol Sci. 2017 Sep;87(3):285-291. (IF 5.408)

14. Weng SY, Yang CY, Li CC, Sun TP, Tung SY, Yen JJ, Tsai TF, Chen CM, Chen SH, Hsiao M, Huang PH, Yang-Yen HF. Synergism between p53 and Mcl-1 in protecting from hepatic injury, fibrosis and cancer. J Hepatol. 2011;54:685-94. (IF 30.083)

15. Weng SY, Schuppan D. AMPK regulates macrophage polarization in adipose tissue inflammation and NASH. J Hepatol. 2013;58: 619-21. (IF 30.083)

16. Chen SH, Wu PS, Chou CH, Yan YT, Liu H, Weng SY, Yang-Yen HF. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 2007;18:2525-32. (IF= 3.612)

研討會論文：：

2. Utilization of AI-aided image classification for the diagnosis of ischemic stroke. The Forum of Long-Term Care in 2021. Jun 2021 Taiwan

3. Rapamycin Promotes Tumoricidal Immunity in Murine HCC Via M1-Type Macrophage and Dendritic Cell Polarization and Enhancement of Cytotoxic T Cells Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting NOV 09-13, 2018 San Francisco, CA

4. Combined Treatment with Rapamycin and Zoledronic Acid Retards Growth of Advanced Murine Hepatocellular Carcinoma Via Activation of Innate and Adaptive Immunity Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting NOV 09-13, 2018 San Francisco, CA

5. Deletion of IL-4 Receptor Alpha on Macrophages Attenuates Inflammation and Fibrosis in Murine Nonalcoholic Steatohepatitis (NASH) Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting NOV 09-13, 2018 San Francisco, CA

6. Dietary Wheat Amylase Trypsin Inhibitors Worsen Chronic Liver Disease in Pre-Clinical Models of Nash and Liver Fibrosis Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting NOV 09-13, 2018 San Francisco, CA

7. Glucagon-like peptide-1 receptor agonists inhibit inflammatory macrophage activation and improve the major components of NASH in an optimized CDAA mouse model 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting OCT 20-24, 2017 Washington, DC

8. A mouse model with inducible ablation of TGFb receptor type 2 limited to hepatic stellate cells predicts the power of HSC-specific TGFb pathway inhibition 68th Annual Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) OCT 20-24, 2017 Washington, DC

9. Zoledronic Acid suppresses tumour associated macrophages and myeloid derived suppressor cells boosting immune modulating therapies against murine HCC 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting OCT 20-24, 2017 Washington, DC

10. Combined treatment with Rapamycin and Zoledronic Acid strongly inhibits growth of murine hepatocellular carcinoma via activation of the immune microenvironment 68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting OCT 20-24, 2017 Washington, DC

11. Nutritional Wheat Amylase Trypsin Inhibitors, Activators of Toll Like Receptor 4, Exacerbate Non-Alcoholic Steatohepatitis in High Fat Diet Fed Mice 67th Annual Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 11-15, 2016 Boston, MA

12. A Short-term High Carbohydrate Diet Induces Acute Liver Injury, Enhanced de novo Lipogenesis, Inflammation, Fibrosis and M2 Macrophage Polarization 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 11-15, 2016 Boston, MA

13. IL-4 and IL-13 regulate liver fibrosis through M2 macrophages, but not Th2 T cells or hepatocytes 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 11-15, 2016 Boston, MA

14. Generation and characterization of a myofibroblasts specific conditional Col3a1a-CreERT2 mouse model to study liver fibrosis 67th Annual Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 11-15, 2016 Boston, MA

15. Combined Treatment with Rapamycin and Zoledronic Acid Synergistically Repolarize Tumour Associated Macrophages towards anti-HCC responses 67th Annual Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 11-15, 2016 Boston, MA

16. The antifibrotic effect of IL-4R alpha signaling depends on macrophage subsets prevalent during liver fibrosis progression and reversal 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 13-17, 2015 San Francisco, CA

17. Glucagon-like peptide-1 potently attenuates steatohepatitis and liver fibrosis by regulating liver macrophage infiltration, activation and polarization 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 13-17, 2015 San Francisco, CA

18. IL-13R alpha 1 signaling and M2 macrophages but not Th2 T cells drive progression of CCL4-induce fibrosis 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 13-17, 2015 San Francisco, CA

19. Oral hepatotropic DPP4 inhibitors attenuate NASH and bilary fibrosis in part through macrophage modulation 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) NOV 13-17, 2015 San Francisco, CA

20. Linagliptin-mediated DPP-4 Inhibition Ameliorates Inflammation and Fibrosis in Models of Biliary Fibrosis and NASH 75th Scientific Sessions of the American-Diabetes-Association JUN 05-09, 2015 Boston, MA

21. Linagliptin mediated DPP-4 inhibition ameliorates inflammation and fibrosis in models of NASH and biliary fibrosis 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease NOV 07-11, 2014 Boston, MA

22. Alternative regulation of macrophages activation by IL-4 receptor alpha in fibrosis progression and reversal 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease NOV 07-11, 2014 Boston, MA

23. Pharmacological modulation of IL-4Ralpha regulates liver fibrosis progression and regression by tuning M2 macrophage polarization 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease NOV 07-11, 2014 Boston, MA

24. A Diet-Induced Mouse Model With Development Of Severe Nash 65th Annual Meeting of the American-Association-for-the-Study-of-Liver-Disease NOV 07-11, 2014 Boston, MA

25. IL-4 Receptor alpha1 regulates M2 macrophage signaling and is an important modulator of liver fibrosis progression and regression 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases NOV 01-05, 2013 Washington, DC

26. Differential regulation of liver fibrosis progression and regression by pharmacological inhibition of M2 macrophage polarization through IL-4Ralpha1 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases NOV 01-05, 2013 Washington, DC

27. Lack of Matrix Metalloproteinase-8 Ameliorates Liver Fibrosis Progression and Promotes Fibrosis Regression 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases NOV 01-05, 2013 Washington, DC

28. A long-acting GLP-1 agonist exenatide suppresses inflammation and fibrosis in models of NASH and biliary fibrosis 64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases NOV 01-05, 2013 Washington, DC

29. Synergism between p53 and Mcl-1 in hepatocyte maturation and survival Second AACR International Conference on Frontiers in Basic Cancer Research--Sep 14-18, 2011; San Francisco, CA